Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, has announced the close of a US$65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company, as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners.
Latham & Watkins LLP represented Gate Bioscience in the funding round with an Emerging Companies & Growth team led by Bay Area partner Kathleen Wells, with associates Christopher Pham and Jack McKay, and assistance from Wes Dantzler.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
